Literature DB >> 16162192

Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies.

Fabrizio Fabrizi1, Paul Martin, Vivek Dixit, Suphamai Bunnapradist, Fasiha Kanwal, Gareth Dulai.   

Abstract

Hepatitis C virus (HCV) infection has a detrimental role on patient and graft survival after renal transplantation (RT). Some studies have also implicated HCV in the development of post-transplant diabetes mellitus (PTDM). We conducted a systematic review of the published medical literature of the relationship between anti-HCV seropositive status and DM after RT. The risk of DM occurrence in anti-HCV-positive and -negative patients after RT was regarded as the most reliable outcome end-point. We used the random effects model of DerSimonian and Laird to generate a summary estimate of the Odds Ratio (OD) of new onset DM in HCV-positive and -negative patients after kidney transplantation. Ten studies involving 2502 unique RT recipients were identified. The incidence of PTDM after RT ranged between 7.9% and 50%. The summary estimate for adjusted OR was 3.97 with a 95% confidence interval (CI) of 1.83-8.61 (p-value for homogeneity <0.0473). Thus, pooling of study results demonstrated the presence of a significant link between anti-HCV seropositive status and DM after RT. This relationship provides one potential explanation for the adverse effects of HCV on patient and graft survival after RT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162192     DOI: 10.1111/j.1600-6143.2005.01040.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  45 in total

1.  Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.

Authors:  Siu-Ka Mak; Ho-Kwan Sin; Kin-Yee Lo; Man-Wai Lo; Shuk-Fan Chan; Kwok-Chi Lo; Yuk-Yi Wong; Lo-Yi Ho; Ping-Nam Wong; Andrew K M Wong
Journal:  Clin Exp Nephrol       Date:  2017-01-12       Impact factor: 2.801

Review 2.  Chronic viral hepatitis in kidney transplantation.

Authors:  Janna Huskey; Alexander C Wiseman
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

Review 3.  Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment.

Authors:  Jessica L Hwang; Roy E Weiss
Journal:  Diabetes Metab Res Rev       Date:  2014-02       Impact factor: 4.876

4.  Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.

Authors:  Junichiro Sageshima; Christoph Troppmann; John P McVicar; Chandrasekar Santhanakrishnan; Angelo M de Mattos; Richard V Perez
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

Review 5.  Hepatitis C infection in hemodialysis patients: A review.

Authors:  Digdem Ozer Etik; Serkan Ocal; Ahmet Sedat Boyacioglu
Journal:  World J Hepatol       Date:  2015-04-28

Review 6.  Kidney transplantation from donors with hepatitis C infection.

Authors:  Massimiliano Veroux; Daniela Corona; Nunziata Sinagra; Alessia Giaquinta; Domenico Zerbo; Burcin Ekser; Giuseppe Giuffrida; Pietro Caglià; Riccardo Gula; Vincenzo Ardita; Pierfrancesco Veroux
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 7.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

8.  Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

Authors:  Donna L White; Vlad Ratziu; Hashem B El-Serag
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

Review 9.  Hepatitis C and its impact on renal transplantation.

Authors:  Jose M Morales; Fabrizio Fabrizi
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

Review 10.  Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.

Authors:  Vijay Shivaswamy; Brian Boerner; Jennifer Larsen
Journal:  Endocr Rev       Date:  2015-12-09       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.